Radioligand Therapy Market to Reach US$ 15.80 Billion by 2033 as Targeted Oncology, Lu-177 Therapies and Theranostics Reshape Precision Cancer Care

According to DataM Intelligence, the radioligand therapy market reached US$ 2.94 billion in 2025 and is expected to reach US$ 15.80 billion by 2033, growing at a 21.9% CAGR during 2026-2033. Radioligand therapy is emerging as a high-value oncology approach because it combines molecular targeting, radioactive payload delivery, companion imaging and specialized nuclear medicine infrastructure into one precision treatment pathway. Unlike conventional systemic oncology drugs, targeted radiotherapy depends on an integrated chain of isotope supply, radiopharmacy preparation, PET-based patient selection, trained treatment centers and post-dose radiation safety controls.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/radioligand-therapy-market?kailas

2026 Official Developments in Radioligand Pipelines, Isotope Supply, Manufacturing Sites and Oncology Programs

1. In May 2026, Novartis announced new radioligand therapy data for ASCO and EHA, including Pluvicto PSMAddition subgroup analyses and Phase 1 actinium-based PSMA radioligand therapy data, reinforcing the company's effort to extend RLT beyond late-line prostate cancer.

2. In March 2026, Lantheus received U.S. FDA tentative approval for Lutetium Lu 177 Dotatate PNT2003, a radioequivalent version of Lutathera for somatostatin receptor-positive GEP-NETs, with final approval dependent on legal and regulatory conditions.

3. In February 2026, Bayer reported final overall survival results from the PEACE-3 trial, where Xofigo plus enzalutamide reduced the risk of death by 24% versus enzalutamide alone in men with metastatic castration-resistant prostate cancer and bone metastases.

4. In February 2026, Curium Group, PeptiDream and PDRadiopharma dosed the first patient in a Japan registrational Phase 2 trial of 177Lu-PSMA-I&T for PSMA-positive metastatic castration-resistant prostate cancer, using 64Cu-PSMA-I&T to confirm PSMA positivity before therapy.

5. In June 2026, Curium announced an investment of more than €32 million in Saclay, France, to create a production line for 177Lu-PSMA-I&T and strengthen European supply capacity for targeted radioligand therapy.

6. In April 2026, Telix and Regeneron announced a strategic radiopharma collaboration covering next-generation radiopharmaceutical therapies, combining Telix's development and manufacturing infrastructure with Regeneron's antibody discovery and oncology capabilities.

Precision Nuclear Medicine Becomes an Infrastructure Market

The radioligand therapy market is growing because oncology is moving toward treatments that identify a molecular target, confirm expression through diagnostic imaging and then deliver a radionuclide payload directly to cancer cells. The FDA's Pluvicto label illustrates this theranostic model: patients are selected using Locametz or another approved PSMA PET product based on PSMA expression in tumors.

This makes theranostics the commercial center of the market. The product is not only the therapeutic dose; the market also depends on PET imaging, radionuclide availability, hot-cell capacity, trained nuclear medicine teams, radiation safety procedures and reimbursement pathways. The FDA label also specifies that radiopharmaceuticals such as Pluvicto should be used by or under the control of qualified healthcare providers with approved training and experience in the safe handling of radiopharmaceuticals.

Drivers, Disruption and Opportunity Areas

Demand is being driven by prostate cancer adoption, neuroendocrine tumor treatment, companion diagnostics, pipeline expansion and the broader need for more precise oncology radiopharmaceuticals. Global cancer statistics maintained by the WHO's International Agency for Research on Cancer continue to support the long-term need for scalable cancer diagnosis and treatment models.

The main disruption is value-chain complexity. Isotope half-life, radiopharmacy scheduling, treatment-center licensing, patient travel, radiation precautions and payer approval can all affect access. Opportunities are strongest in new targets, alpha emitters such as actinium-225, next-generation PSMA programs, SSTR-targeted neuroendocrine tumor therapies, manufacturing partnerships and regional treatment networks.

Request a Customized Report According to Your Business Strategy: https://www.datamintelligence.com/customize/radioligand-therapy-market?kailas

USA Market: Commercial Scale, Site Density and Reimbursement Discipline

The USA is the most important near-term commercialization market because it combines FDA regulatory clarity, large oncology networks, Medicare payment infrastructure, high PSMA PET utilization and expanding community treatment capacity. Novartis reported in its Q1 2026 investor presentation that Pluvicto sales grew 70% in constant currency, driven by USA pre-taxane mCRPC demand and continued ex-U.S. rollout; the company also reported more than 830 U.S. sites, up 30% year over year, with approximately nine out of ten patients within 30 miles of a treatment site.

The USA market is also shifting from academic-only delivery to a broader network model. Novartis noted that U.S. new-to-brand prescription growth was strongest in community settings, which matters because radioligand therapy cannot scale if capacity remains concentrated only in elite cancer centers.

Commercial success in the USA will depend on three issues: reliable isotope supply, predictable scheduling and reimbursement execution. CMS's 2026 Physician Fee Schedule framework reinforces the importance of correct coding, payment-rate visibility and provider economics for advanced nuclear medicine procedures.

Japan Market: Theranostic Entry, Local Bridging and Manufacturing Logic

Japan is becoming one of the most strategically important Asia-Pacific markets because it is building radioligand therapy through a complete theranostic pathway rather than a single-product model. Novartis Japan announced in September 2025 that Pluvicto was approved as Japan's first targeted radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer; the same official release also listed Locametz Kit for PSMA-targeted therapy eligibility support and GalliaPharm 68Ge/68Ga generator for PET radiolabeling.

This matters commercially because Japan's market access story is tied to clinical readiness. PMDA's Pluvicto product information identifies Novartis Pharma K.K. as the marketing authorization holder and links product labeling, patient guides, risk-management materials and review documentation for healthcare professionals.

Japan's second growth layer is domestic clinical development and local manufacturing transfer. Curium's 2026 Japan trial with PeptiDream and PDRadiopharma is important because PDRadiopharma is expected to lead regulatory filing, manufacturing, commercialization and distribution activities in Japan, while Curium supports technology transfer and manufacturing-line setup.

Germany anchors Europe's radiopharmaceutical supply chain through companies such as ITM Isotope Technologies Munich SE, which highlights Lutetium-177, Actinium-225 and Terbium-161 in its isotope portfolio and advances targeted radiopharmaceutical pipelines. South Korea is relevant because of its high-income healthcare system, major oncology centers and growing nuclear medicine ecosystem; WHO classifies the country as a high-income market with advanced health expenditure capacity.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=radioligand-therapy-market?kailas

Key Players and Competitive Profiles

DataM identifies major and emerging players including Novartis AG, Bayer AG, Eli Lilly and Company, Lantheus, Curium, AstraZeneca, ITM Isotope Technologies Munich SE, Telix Pharmaceuticals, Orano Med, Sanofi, RadioMedix, Clarity Pharmaceuticals, Ariceum Therapeutics and Blue Earth Therapeutics.

Novartis leads through Pluvicto and Lutathera, supported by treatment-site expansion and next-generation RLT data. Its competitive advantage is a combined portfolio, manufacturing network and physician-access infrastructure.

Bayer remains relevant through Xofigo, an alpha-emitting radiopharmaceutical for prostate cancer with symptomatic bone metastases. The 2026 PEACE-3 survival data strengthens its role in combination-driven targeted radiotherapy.

Curium is moving from diagnostics strength into therapeutic radioligands. Its 2026 Saclay investment and Japan registrational trial show a strategy centered on production scale, PSMA therapy and regional access.

Lantheus is positioning itself through radiopharmaceutical depth and lifecycle competition. FDA tentative approval for PNT2003 gives it a potential role in broadening GEP-NET treatment access once final approval conditions are met.

Conclusion: Value-Chain Intelligence Will Decide the Winners

The radioligand therapy market is no longer only a drug-development story. It is a precision nuclear medicine value chain built around isotopes, diagnostics, manufacturing, radiopharmacy logistics, treatment-site density and reimbursement execution. The strongest companies will be those that can secure isotope supply, expand clinical evidence, localize access in the USA and Japan, and help hospitals convert complex targeted radiotherapy into repeatable oncology infrastructure.

Read Exclusive Report Description: https://www.datamintelligence.com/research-report/radioligand-therapy-market

Contact:
Fabian Mathew
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a global market research and business intelligence firm delivering actionable insights across healthcare, pharmaceuticals, chemicals, energy, technology, food, and industrial sectors. Through syndicated reports, custom research, consulting, and competitive intelligence services, the company helps organizations identify growth opportunities, navigate market challenges, and make informed strategic decisions in over 50+ countries worldwide.

This release was published on openPR.